国产首个!亚盛医药 Bcl-2 抑制剂国内获批上市

新浪医药
Jul 11

7 月 10 日,NMPA 官网显示,亚盛医药利沙托克拉片(APG-2575)获批上市,用于治疗既往经过至少包含BTK抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者。此前该适应症已被纳入优先审评(受理号:CXHS2400112/3/4)截图来源:NMPA 官网APG-2575 是亚盛医药自主研发的新型口服 Bcl-2 选择性抑制剂,可通过选择性抑制BCL-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10